Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment. - Test2 - elhamkhani - TriplyDB

Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment.

Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment.

http://www.wikidata.org/entity/Q37344738

about

Opioid antagonists for alcohol dependence The role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical review Using Ecological Momentary Assessment (EMA) to Assess Situation-Level Predictors of Alcohol Use and Alcohol-Related Consequences Improving clinical outcomes for naltrexone as a management of problem alcohol use Medications for unhealthy alcohol use: across the spectrum.Pharmacogenetics of OPRM1.A principal components analysis of the abbreviated Desires for Alcohol Questionnaire (DAQ).Ecological momentary assessment (EMA) in studies of substance use Placebo group improvement in trials of pharmacotherapies for alcohol use disorders: a multivariate meta-analysis examining change over time.A pharmacogenetic model of naltrexone-induced attenuation of alcohol consumption in rhesus monkeys Characterizing subjective responses to alcohol among adolescent problem drinkers OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models.Pharmacogenetics of alcohol and alcohol dependence treatment Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation.Relationship between momentary affect states and self-efficacy in adolescent smokers The Effects of Naltrexone Among Alcohol Non-Abstainers: Results from the COMBINE Study.The DRD4 exon 3 VNTR polymorphism and addiction-related phenotypes: a review.Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation.Biobehavioral mechanisms of topiramate's effects on alcohol use: an investigation pairing laboratory and ecological momentary assessments Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study.Ambulatory monitoring in the genetics of psychosomatic medicine.Gender Considerations in Addiction: Implications for Treatment.An event-level investigation of hangovers' relationship to age and drinking.Effects of naltrexone and LY255582 on ethanol maintenance, seeking, and relapse responding by alcohol-preferring (P) rats.Cigarette smoking predicts differential benefit from naltrexone for alcohol dependence.Naltrexone decreases heavy drinking rates in smoking cessation treatment: an exploratory study.Naltrexone improves quit rates, attenuates smoking urge, and reduces alcohol use in heavy drinking smokers attempting to quit smoking.Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment.Subjective responses to alcohol consumption as endophenotypes: advancing behavioral genetics in etiological and treatment models of alcoholism.Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues.Effects of naltrexone on cortisol levels in heavy drinkers.Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol.A pilot study of naltrexone and BASICS for heavy drinking young adults.Initial evidence of an association between OPRM1 and adolescent alcohol misuse Polymorphisms of the mu-opioid receptor and dopamine D4 receptor genes and subjective responses to alcohol in the natural environment.The genetics of the opioid system and specific drug addictions Effects of naltrexone on adolescent alcohol cue reactivity and sensitivity: an initial randomized trial.Effects of alcoholism typology on response to naltrexone in the COMBINE study.Understanding naltrexone mechanism of action and pharmacogenetics in Asian Americans via behavioral economics: a preliminary study.

P2860

Q24235797-A529284D-657C-4A93-A98D-25F1BA16D455 Q24616528-F5DA4005-56EE-4B4B-848D-A3B7B08143BB Q26799855-69896881-1C6B-41E6-BB8C-CA18771CF466 Q27021406-7BD4D983-7E99-4EC2-982B-CC9D5C1F785C Q27690692-E8B4A70F-2ECC-4CA8-B9EE-6054D5A84D27 Q33568294-3EB70ACD-1082-4C89-9729-DAA8D516C22E Q33624918-7E734BC7-AE22-452F-91B6-C2B8825A103C Q33757038-1B05769B-F949-422D-978F-84A060534B4A Q33828162-BF8D8287-3ABD-44C7-ABC5-CC3BF32B8AFA Q33872457-2903B39B-0A00-4D36-87C9-6312353035F7 Q33915640-1E56B114-8833-49FE-B8B5-94088D754360 Q33921223-D051D6C6-7009-4E27-9EA9-A9260A169BDB Q34081709-D0F0CAC9-61F0-4523-8C8D-3925F97ABB04 Q34306652-9FAB8CD1-DADB-4B86-8834-70E1E806873E Q34311649-3E10F37A-11D9-4F96-AD61-95F103A2F58E Q34602493-757B9A19-A6C1-4E27-88DF-76094A9535AA Q34689570-6347C2A1-F8EF-4C1F-AA94-D5B11C9165CB Q34972111-DD84DAC3-E97B-4B5E-A30D-60EC49DBF6EE Q34982437-AF13C1C3-1960-4BAB-B28D-F39D9A353B09 Q35553786-8A394D05-9EDA-48AD-8324-FFEDD70CC8C3 Q35622645-841E036B-4138-47AB-BBD1-3E0564C11E05 Q36041596-530AB948-8493-4213-86F4-A648F11C9670 Q36082618-CA6EAB2E-482E-4034-B9C9-0FE5F7EA6642 Q36083472-1F5429AF-0F76-4FDD-8E03-B9367C567BF9 Q36090024-028004D0-2CA0-411B-830E-490D455BE311 Q36133717-8DF84691-58D2-4918-9202-B44B4319319D Q36223647-436A3B27-7D3C-46EC-BCA1-4276A8E270FD Q36263819-A3276B4F-F5EA-4A9E-B3E5-C18FF625E983 Q36322822-44EA7493-F0B7-45B3-8713-FC98EF36EC47 Q36436395-F0667B9D-09B2-4080-8180-01ABE131E89C Q36540015-30403BD9-E7F5-4B0B-9F61-1D74AA984682 Q36863387-ECEF6452-F065-4339-BC2F-5CD8C35F3118 Q36931792-A99363FE-9C65-4703-9C10-54687C9AAC85 Q36939060-49281651-FB64-45AE-82FD-81CEB1069B3A Q36952699-CC6385E6-2550-4EEE-8BC3-680CCE7E5623 Q36989434-539CDEBA-B9AC-4336-A4BA-38988146FB22 Q37040492-151818B8-D961-46D5-8194-E5CF0C78DD52 Q37059531-3381F829-FEEC-4291-BEA5-F370831A5B4B Q37060490-71644A45-2546-4AC8-9408-01849F2E721B Q37089324-C606A1D1-806E-4571-907D-3AB6ACFAAAE5

P2860

Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment.

http://www.wikidata.org/entity/Q37344738

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Moderators of naltrexone's eff ...... rs in the natural environment.

@en

Moderators of naltrexone's eff ...... rs in the natural environment.

@nl

type

label

Moderators of naltrexone's eff ...... rs in the natural environment.

@en

Moderators of naltrexone's eff ...... rs in the natural environment.

@nl

prefLabel

Moderators of naltrexone's eff ...... rs in the natural environment.

@en

Moderators of naltrexone's eff ...... rs in the natural environment.

@nl

P1433

Q37344738-1A6373CA-6054-4CEF-B6CC-C4B2E577D418

P1476

Q37344738-3480363D-2082-43A4-AA8C-517DC7CA1392

P2093

Q37344738-02DA0606-4033-4359-9575-DBA88C0D50F0

Q37344738-2D1676CA-FF9B-4032-9C81-EF62D3461A97

Q37344738-46C51A9A-5D6E-425E-9169-7A37306E451C

Q37344738-5047CA44-DF06-408E-8F05-B8D465F783A8

Q37344738-5B6A4B74-A208-4F35-B118-60B5D11FF6D9

Q37344738-600B7ED3-7F61-4DB4-B947-FC16B067CE25

Q37344738-6723781F-F8CE-4224-A11C-21953138C47F

Q37344738-6EC44F73-2D0E-4047-AC53-77DD4F54AB6B

Q37344738-B90532B5-2DB2-4E6E-85D9-035224D2D32F

Q37344738-C2AE1098-DEF3-4910-ABF3-7F42D8845AAA

P2860

Q37344738-06836B58-9D51-4046-9875-8F92F9C6575C

Q37344738-0CF1C9F4-9271-4B2A-B91E-F04845EF31E3

Q37344738-10CC855C-FC4A-419C-BEB6-94423071FAF3

Q37344738-19DDCF2C-6390-45E1-9C9F-2376E1501486

Q37344738-1E803E71-CB21-4C5A-A731-A5E55AEC6BD5

Q37344738-1F6C558F-FE1F-4FCC-BD84-100AA53730E1

Q37344738-22A06151-8572-433E-8205-0A4BB965C7D5

Q37344738-24E63793-4EB2-4C95-B37A-748CFBA3749E

Q37344738-28867359-6E91-4B5D-AFD1-2F0A04D73151

Q37344738-2DDCBAC1-AB20-4200-B954-56E1FAA18FBE

P304

Q37344738-B56AA4FD-C849-4FE9-966A-C2593A227B59

P31

Q37344738-CA123866-FD37-4E5E-98A4-9AFFEA8E039A

P356

Q37344738-7DD6C362-F335-44E6-8861-5CDBDB69FFBB

P433

Q37344738-1E5137E5-F135-43C3-B45D-EAAA915E4678

P478

Q37344738-EFAC2C45-D860-4B9F-AAC9-D08A331D62C8

P577

Q37344738-5349E338-8858-4D01-91BA-5D3C685E1554

P5875

Q37344738-50AD3358-1DB6-4C4C-95CE-53B253B2CDD9

P698

Q37344738-7E0B7EC7-8DBB-4019-9ABC-13A99059D0DF

P921

Q37344738-E13B96C5-E383-4645-A043-E825EA8DDF86

P932

Q37344738-D3C8D79C-373E-4A10-9EB7-EF315B8B3641

P356

J.1530-0277.2007.00545.X

P1433

Alcoholism: Clinical and Experimental Research

P1476

Moderators of naltrexone's eff ...... rs in the natural environment.

@en

P2093

Chad J Gwaltney

http://www.w3.org/2001/XMLSchema#string

Damaris J Rohsenow

http://www.w3.org/2001/XMLSchema#string

David B Abrams

http://www.w3.org/2001/XMLSchema#string

James MacKillop

http://www.w3.org/2001/XMLSchema#string

Jean A Paty

http://www.w3.org/2001/XMLSchema#string

Jennifer W Tidey

http://www.w3.org/2001/XMLSchema#string

John E McGeary

http://www.w3.org/2001/XMLSchema#string

Peter M Monti

http://www.w3.org/2001/XMLSchema#string

Robert M Swift

http://www.w3.org/2001/XMLSchema#string

Robert Miranda

http://www.w3.org/2001/XMLSchema#string

P2860

Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication

Olanzapine reduces craving for alcohol: a DRD4 VNTR polymorphism by pharmacotherapy interaction

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

Naltrexone alters subjective and psychomotor responses to alcohol in heavy drinking subjects.

Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis.

Models for longitudinal data: a generalized estimating equation approach.

Naltrexone in the treatment of alcohol dependence.

Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review.

Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers.

Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials.

P304

58-66

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1530-0277.2007.00545.X

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P577

2007-11-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5817939

http://www.w3.org/2001/XMLSchema#string

P698

18028530

http://www.w3.org/2001/XMLSchema#string

P921

P932

2743136

http://www.w3.org/2001/XMLSchema#string